Subtle Medical Raises $33M, Names Ohad Arazi CEO
Key insights
- Subtle Medical's $33M Series C brings total funding to $86M, with named health system customers including Mount Sinai, RadNet, and Radiology Partners.
- The AI imaging software cuts scan times by up to 80% on existing scanner hardware across more than 1,300 global deployments.
- New CEO Ohad Arazi joins from Change Healthcare and Zebra Medical Vision while co-founder Enhao Gong steps into the Chief Science Officer role.
Why this matters
Installing Ohad Arazi, a CEO with direct healthcare IT commercialization experience at Change Healthcare and Zebra Medical Vision, signals that Subtle Medical has cleared the product-market fit stage and is now executing a go-to-market scale-up, a materially different operational challenge. The presence of named enterprise customers including Mount Sinai, RadNet, and Radiology Partners gives the $86 million capital stack real proof points rather than a pre-revenue growth narrative, which changes the risk profile for follow-on investors and acquirers watching the space. SubtleGAD's research-stage finding of 90% gadolinium dose reduction, if it reaches FDA clearance, moves Subtle Medical from a workflow efficiency vendor into a patient safety and cost-reduction vendor, a significantly stickier and higher-margin procurement category for hospital systems.
Summary
Subtle Medical closed a $33 million Series C led by Morgan Stanley Expansion Capital, bringing total capital raised to $86 million and installing Ohad Arazi as CEO. Arazi joins from Change Healthcare, Zebra Medical Vision, and Clarius Mobile Health. Co-founder Enhao Gong becomes Chief Science Officer.
The AI software cuts scan times by up to 80% on existing scanner hardware, with flagship products SubtleHD and SubtlePET deployed across more than 1,300 scanners globally. Named customers include Mount Sinai, RadNet, and Radiology Partners.
Essentially: (Subtle Medical, Morgan Stanley Expansion Capital) are betting a software layer can unlock imaging capacity at health systems without requiring capital-intensive scanner replacement.
- Investors include Shinhan Venture Investment, Fusion Fund, EnvisionX, BRV, and returning Samsung Ventures.
- SubtleGAD is in development targeting 90% gadolinium contrast dose reduction.
- The AI Imaging Hub unifies control across MRI, PET, and CT from a single platform.
The round funds global commercial expansion of a platform Arazi frames not as a point solution but as the AI layer where health systems run their imaging.
Potential risks and opportunities
Risks
- Established scanner manufacturers with bundled AI software platforms could absorb scan-acceleration capabilities into firmware, undercutting the case for a separate vendor-neutral software layer at health systems like RadNet and Radiology Partners.
- SubtleGAD's 90% gadolinium dose reduction rests on research data; real-world clinical divergence at scale could delay FDA clearance and eliminate the company's most differentiated pipeline asset before it reaches revenue.
- Morgan Stanley Expansion Capital's growth-stage mandate implies near-term revenue ramp expectations; if enterprise sales cycles at health systems prove longer than anticipated, the $86 million total deployed creates significant pressure on Arazi in his first 18 months as CEO.
Opportunities
- Hospital systems facing imaging backlogs without capital scanner budgets are natural buyers: Subtle Medical's software-only upgrade path bypasses the multi-year hardware procurement cycle entirely, which is the central bottleneck Kevin Han at Morgan Stanley Expansion Capital explicitly cited.
- Samsung Ventures returning as an investor opens potential distribution leverage across Samsung healthcare networks in Asia-Pacific markets, where MRI throughput constraints are acute and hardware replacement cycles are long.
- SubtleGAD's 90% gadolinium dose reduction data positions Subtle Medical for co-development or co-marketing conversations with contrast manufacturers and health systems facing growing scrutiny over gadolinium retention in patients.
What we don't know yet
- SubtleGAD's FDA clearance timeline is not disclosed, leaving the commercial availability window for the 90% gadolinium dose reduction product unknown.
- The article names Mount Sinai, RadNet, and Radiology Partners as customers but does not disclose contract values or scanner volumes, making it impossible to gauge revenue scale relative to $86 million raised.
- Whether the AI Imaging Hub interoperates with all major scanner manufacturer platforms or only select vendors is unspecified, which is material to the vendor-neutral claim at the core of the commercial pitch.
Originally reported by prnewswire.com
Read the original article →Original headline: Subtle Medical Raises $33M Series C, Names Ohad Arazi CEO to Scale AI Medical Imaging Platform Across 1,300+ Scanners Globally